Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1645 1654 1658 1675
This examiner grants 33% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18279931 | PHOTOCAGED CITRULLINE ANALOGS AND METHODS FOR SITE-SPECIFIC INCORPORATION OF CITRULLINE INTO PROTEINS | Non-Final OA | University of Massachusetts |
| 18269716 | METHOD FOR PRODUCING LIPIDIC PEPTIDE | Non-Final OA | NISSAN CHEMICAL CORPORATION |
| 18432185 | TREATMENT OF HYPOPARATHYROIDISM | Final Rejection | Entera Bio Ltd. |
| 17403357 | COMPOSITIONS COMPRISING A DELIVERY AGENT AND PREPARATION THEREOF | Non-Final OA | Novo Nordisk A/S |
| 18338700 | METHOD FOR PRODUCING PEPTIDE, PROTECTIVE GROUP-FORMING REAGENT, AND CONDENSED POLYCYCLIC COMPOUND | Non-Final OA | FUJIFILM Corporation |
| 18019851 | THERAPEUTIC TARGETING OF PHOSPHATE DYSREGULATION IN CANCER VIA THE XPR1:KIDINS220 PROTEIN COMPLEX | Final Rejection | Dana-Farber Cancer Institute, Inc. |
| 17597925 | ANTIMICROBIAL THERAPY THROUGH THE COMBINATION OF PORE-FORMING AGENTS AND HISTONES | Final Rejection | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 18259092 | METHODS OF TREATING, DIAGNOSING AND PREDICTING PROGNOSIS OF SEPSIS | Non-Final OA | University of Rochester |
| 16972800 | Compositions of Transforming Growth Factor-Beta Type III Receptor and Uses for Ossification | Final Rejection | Emory University |
| 17633631 | METHODS OF MAKING INCRETIN ANALOGS | Final Rejection | ELI LILLY AND COMPANY |
| 17438692 | PRESERVED FORMULATIONS | Non-Final OA | Eli Lilly and Company |
| 18578343 | IL-2 MUTEINS FOR TREATING CANCER OR INFECTION | Non-Final OA | Merck Sharp & Dohme LLC |
| 17747952 | SOLID PHASE PEPTIDE SYNTHESIS METHODS AND ASSOCIATED SYSTEMS | Non-Final OA | Massachusetts Institute of Technology |
| 17608025 | METHODS AND COMPOSITIONS INVOLVING TERT ACTIVATING THERAPIES | Final Rejection | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 18567010 | SELECTIVE PENICILLAMINE SUBSTITUTION ENABLES DEVELOPMENT OF A POTENT ANALGESIC PEPTIDE THAT ACTS THROUGH A NON-OPIOID BASED MECHANISM | Non-Final OA | University of Utah Research Foundation |
| 18557801 | CYCLIC PEPTIDE INHIBITORS OF USP22 | Non-Final OA | THE JOHNS HOPKINS UNIVERSITY |
| 18253231 | PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA)-TARGETED PRODRUG FOR SELECTIVE KILLING OF CELLS EXPRESSING PSMA | Non-Final OA | The Johns Hopkins University |
| 18030876 | PEPTIDE INHIBITORS OF GLIOMA-ASSOCIATED ONCOGENE DERIVED FROM THE COILED-COIL DIMERIZATION DOMAIN OF Kif7 | Non-Final OA | The General Hospital Corporation |
| 17780843 | NEONATAL FIBRIN SCAFFOLDS FOR PROMOTING WOUND HEALING | Non-Final OA | North Carolina State University |
| 18339817 | NOVEL CYCLIC PEPTIDES BASED ON NANOBIOSTRUCTURAL CONTROL, PEPTIDESOMES WITH CORE/SHELL STRUCTURE COMPRISING SAME, AND USES THEREOF | Final Rejection | UIF (University Industry Foundation), Yonsei University |
| 18551271 | NOVEL PEPTIDE-OLIGONUCLEOTIDE CONJUGATE AND USE THEREOF | Final Rejection | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy